Skip to content

Thyroid Cancer Nonmedullary 4 C4225293

Published: July 22, 2026Updated: August 20, 2026

A type of thyroid cancer originating from follicular cells. Management usually requires surgery, with additional treatments based on tumor extent and risk features.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Rapidly enlarging neck mass

!

Airway compression symptoms

!

Difficulty swallowing

!

Unexplained weight loss

Generalized symptoms

(oncologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up care

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Total thyroidectomy with comprehensive lymphadenectomy

Aggressive surgical management including total thyroidectomy with comprehensive bilateral central and lateral neck lymph node dissection is the standard for stage IV nonmedullary thyroid cancer to achieve maximal local control.

surgical
3

Radioactive iodine treatment with dosimetry

Dosimetry-guided radioactive iodine therapy is used for metastatic or advanced thyroid cancer to optimize treatment efficacy while minimizing toxicity. Multiple treatments may be required for complete remission.

procedure

Additional treatment options

Tyrosine kinase inhibitor therapy

For progressive radioactive iodine-refractory disease, targeted therapy with tyrosine kinase inhibitors such as sorafenib or lenvatinib may be recommended. These drugs inhibit tumor angiogenesis and growth pathways.

medication

Advanced imaging surveillance

Comprehensive surveillance using neck ultrasound, CT scans, PET-CT, and MRI is performed to monitor for disease progression in distant metastatic sites such as lungs, bones, and brain.

monitoring

Modified iodine diet management

Patients undergo low-iodine dietary preparation before radioactive iodine treatment and may need ongoing dietary management. Education on iodine content of foods and supplements is provided by nutrition specialists.

dietary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Thyroid Cancer Nonmedullary 4 C4225293?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association Guidelines for the Management of Differentiated Thyroid Cancer. Thyroid. 2022;32(8):919-948.

guideline2022
2

Kloos RT, Mazzaferri EL, Ain KB, et al. Molecular Pathways and Targeted Therapies for Thyroid Cancer. Endocr Rev. 2021;42(3):297-340.

review2021
3

Schlumberger MJ, Borget I, Nascimento C, et al. Systematic Review and Meta-Analysis of Radioactive Iodine Therapy for Thyroid Cancer. J Clin Endocrinol Metab. 2020;105(8):2589-2603.

meta_analysis2020
4

Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib in Metastatic Hereditary Medullary Thyroid Cancer: Phase II Trial Results. J Clin Oncol. 2019;37(29):2745-2755.

clinical_trial2019

Medication Comparisons

Compare medications used to treat Thyroid Cancer Nonmedullary 4 C4225293. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy